Clinical Trials Browser

Anatomic Stage II Breast Cancer AJCC v8

Liposarcoma, Histiocytoma, Malignant Fibrous

Burkitt Lymphoma

Lymphoma, Large B-Cell, Diffuse

Leiomyosarcoma, Neoplasms

Lymphoma, Follicular

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

Neuroblastoma, Ganglioneuroblastoma

Pleuropulmonary blastoma

Urinary Bladder Neoplasms

Hodgkin Disease

Endometrial Neoplasms

Heart Failure, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating, Cardiotoxicity

Lymphoma, B-Cell, Marginal Zone

Ovarian Neoplasms

Lymphoma, Follicular

Anatomic Stage I Breast Cancer AJCC v8

Lymphoma, T-Cell, Peripheral

Lymphoma, T-Cell, Peripheral

Hepatoblastoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Endometrial Neoplasms

Lymphoma, Follicular

Hodgkin Disease

Ovarian Neoplasms

Lymphoma, Large B-Cell, Diffuse

Neuroblastoma

Clinical Trials

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

MK-2140-010

SaLuDo

OLYMPIA-1

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

EPCORE™FL-2

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

RADAR

Fern-EC-01

HO170DLBCL

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

CRESCENDO

CIRSARC

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

LBL 2018

Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

MorningLyte

HL-Russia-1

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

FIBROSARC

Genotype-guided Treatment in DLBCL

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)